Company Interview / ResMed capitalising on a "once-in-a-generation" opportunity

Mick Farrell of ResMed highlights the company's impressive quarterly performance with a global top-line growth of 10% and a 29% rise in earnings per share. He notes increased interest from pharmaceutical firms and consumer tech giants like Apple (NASDAQ:AAPL) and Samsung in sleep apnea solutions.

Gross margins were slightly below market expectations due to foreign exchange factors, but Mick emphasises ResMed's year-on-year improvement by over 200 basis points. He foresees continuous investments in technology and supply chain efficiencies to maintain strong margins.

Mick discusses the significant impact of consumer tech companies on sleep health, predicting a rise in patient engagement through wearables. He also touches upon potential impacts of US policies on taxes and tariffs, suggesting possible benefits for ResMed.